ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free MOR Stock Alerts €68.00 0.00 (0.00%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range€67.50▼€68.2050-Day Range€65.65▼€69.3552-Week Range€14.52▼€69.75Volume21,939 shsAverage Volume153,687 shsMarket Capitalization$2.56 billionP/E RatioN/ADividend Yield1.26%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get MorphoSys alerts: Email Address Ad Stansberry ResearchWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted the 2008 housing crisis and the 2022 sell-off… Now, he says that despite the bull market, he's worried older Americans are holding the WRONG stocks in their portfolios for this stage of their lives. So, he's urging folks to buy "America's No. 1 Legacy Stock," which could help them build wealth they could pass on for generations.Learn more here. About MorphoSys Stock (ETR:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesMay 17, 2024 | benzinga.comLatest News for MorphoSys Stock (NASDAQ:MOR)May 16, 2024 | msn.comMorphoSys gains after Novartis discloses all tender offer conditions were metMay 2, 2024 | finance.yahoo.comUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionApril 30, 2024 | seekingalpha.comMorphoSys: Hold Rating Until The Novartis Deal ClosesApril 29, 2024 | msn.comGermany stocks mixed at close of trade; DAX down 0.16%April 28, 2024 | msn.comNew safety risk for MorphoSys drug could complicate Novartis deal - STATApril 28, 2024 | markets.businessinsider.comMorphoSys earnings: here's what Wall Street expectsApril 24, 2024 | finance.yahoo.comMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual MeetingApril 11, 2024 | msn.comGerman biopharma MorphoSys recommends Novartis offer be acceptedApril 11, 2024 | finanznachrichten.deNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesApril 11, 2024 | finance.yahoo.comNovartis tender offer for MorphoSys AG commencesApril 11, 2024 | msn.comNovartis commences tender offer for MorphoSysApril 11, 2024 | msn.comNovartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | finance.yahoo.comUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysApril 4, 2024 | seekingalpha.comNovartis: Higher Guidance, Now A BuyMarch 22, 2024 | markets.businessinsider.comEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActMarch 15, 2024 | finance.yahoo.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | benzinga.comMorphoSys: Q4 Earnings InsightsMarch 12, 2024 | msn.comGerman regulators approve Novartis deal to buy drugmaker MorphosysFebruary 15, 2024 | finance.yahoo.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 8, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreFebruary 7, 2024 | realmoney.thestreet.comMorphoSys just downgraded at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | seekingalpha.comNovartis And MorphoSys Are A Perfect MatchSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees464Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€5.53) Trailing P/E RatioN/A Forward P/E Ratio322.58 P/E Growth0.06Net Income$-468,570,000.00 Net Margins-190.61% Pretax MarginN/A Return on Equity-183.80% Return on Assets-13.84% Debt Debt-to-Equity Ratio3,454.18 Current Ratio1.38 Quick Ratio3.49 Sales & Book Value Annual Sales$241.47 million Price / Sales10.62 Cash Flow€131.17 per share Price / Cash Flow0.52 Book Value(€6.96) per share Price / Book-9.77Miscellaneous Outstanding Shares37,720,000Free FloatN/AMarket Cap$2.56 billion OptionableNot Optionable Beta0.60 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.76MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $705.82kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $474.1kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsBiotest AktiengesellschaftETR:BIOMedigeneETR:MDG1GenfitEPA:GNFTCarl Zeiss MeditecETR:AFXSartorius AktiengesellschaftETR:SRTView All Competitors MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed in 2024? MorphoSys' stock was trading at €34.00 on January 1st, 2024. Since then, MOR shares have increased by 100.0% and is now trading at €68.00. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), MercadoLibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA). This page (ETR:MOR) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this sum...StockEarnings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.